ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v10i4.756ppharm-196Research ArticleЛЕКЦИЯLECTUREДЕТСКАЯ АСТМА: КЛЮЧЕВЫЕ ПРИНЦИПЫ ДОСТИЖЕНИЯ КОНТРОЛЯ НА СОВРЕМЕННОМ ЭТАПЕINFANT ASTHMA: KEY PRINCIPLES OF CONTROL ATTAINMENT IN THE MODERN STAGEВишнёваЕ.А.VishnevaE.A.Намазова-БарановаЛ. С.Namazova-BaranovaL. S.АлексееваА. А.AlekseevaA. A.ЭфендиеваК. Е.EfendievaK. E.ЛевинаЮ. Г.LevinaYu. G.ВознесенскаяН. И.VoznesenskayaN. I.СелимзяноваЛ. Р.SelimzyanovaL. R.ТомиловаА. Ю.TomilovaA. Yu.ПромысловаЕ. А.PromyslovaE. A.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children’s Health, MoscowRussian FederationНаучный центр здоровья детей РАМН, Москва Первый Московский государственный медицинский университет им. И.М. Сеченова Российский национальный исследовательский медицинский университет имени Н.И. Пирогова, МоскваРоссияScientific Center of Children’s Health, Moscow First Sechenov Moscow State Medical University Pirogov Russian National Medical Research University, MoscowRussian FederationНаучный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children’s Health, Moscow First Sechenov Moscow State Medical UniversityRussian FederationНаучный центр здоровья детей РАМН, Москва Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Center of Children’s Health, Moscow First Sechenov Moscow State Medical UniversityRussian FederationНаучный центр здоровья детей РАМН, Москва Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Center of Children’s Health, MoscowRussian Federation201314082013104Педиатрическая фармакология6072Copyright © Вишнёва Е., Намазова-Баранова Л.С., Алексеева А.А., Эфендиева К.Е., Левина Ю.Г., Вознесенская Н.И., Селимзянова Л.Р., Томилова А.Ю., Промыслова Е.А., 20132013Вишнёва Е., Намазова-Баранова Л.С., Алексеева А.А., Эфендиева К.Е., Левина Ю.Г., Вознесенская Н.И., Селимзянова Л.Р., Томилова А.Ю., Промыслова Е.А.Vishneva E., Namazova-Baranova L.S., Alekseeva A.A., Efendieva K.E., Levina Y.G., Voznesenskaya N.I., Selimzyanova L.R., Tomilova A.Y., Promyslova E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/196

The article is dedicated to the issue of bronchial asthma in children. Immaturity of respiratory and immune systems, peculiarities of the disease course, difficulty in establishing diagnosis and selecting delivery devices for drugs and a limited amount of evidence-based recommendations determine the current situation: only few guides touch upon the subject of infant asthma management. Although asthma is the most widespread disease of lower respiratory tract in children, a significant number of patients do not receive adequate treatment, which is why they cannot control asthma. The authors of this article analyzed the most up-to-date documents (ICON, GINA, PRACTALL, NAEPP, SIGN) that touch upon this subject and briefly stated the key principles of attaining control over this nosology in order to increase availability, spread and introduction of standard therapy of infant asthma.

бронхиальная астмаклассификацияпатогенезклиническое течениелечениеконтроль болезнидетиbronchial asthmaclassificationpathogenesisclinical coursetreatmentdisease controlchildrenReferencesBaiz N., Annesi-Maesano I. Is the asthma epidemic still ascending? Clin Chest Med. 2012; 33 (3): 419–29. Doi: 10.1016/j.ccm. 2012.06.001. Epub 2012 Jul 18.Baiz N., Annesi-Maesano I. Is the asthma epidemic still ascending? Clin Chest Med. 2012; 33 (3): 419–29. Doi: 10.1016/j.ccm. 2012.06.001. Epub 2012 Jul 18.Global Atlas of Asthma Published by the European Academy of Allergy and Clinical Immunology 2013. Available from: http://www.eaaci.orgGlobal Atlas of Asthma Published by the European Academy of Allergy and Clinical Immunology 2013. Available from: http://www.eaaci.orgTrends in Asthma Prevalence, Health Care, and Mortality in the United States, 2001–2010. CDC. May 2012. Available from: http://www.aaaai.orgTrends in Asthma Prevalence, Health Care, and Mortality in the United States, 2001–2010. CDC. May 2012. Available from: http://www.aaaai.orgВишнева Е.А., Намазова-Баранова Л.С. Бронхиальная астма у детей младше 8 лет: как снизить частоту обострений и госпитализаций? Педиатрическая фармакология. 2009; 6 (1): 51–54.Вишнева Е.А., Намазова-Баранова Л.С. Бронхиальная астма у детей младше 8 лет: как снизить частоту обострений и госпитализаций? Педиатрическая фармакология. 2009; 6 (1): 51–54.From the Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger. Global Initiative for Asthma (GINA). 2009. Available from: http://www.ginasthma.org/From the Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger. Global Initiative for Asthma (GINA). 2009. Available from: http://www.ginasthma.org/From the Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). 2011. Available from: http://www.ginasthma.orgFrom the Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). 2011. Available from: http://www.ginasthma.orgBacharier L. B., Boner A., Carlsen K. H., Eigenmann P. A., Frischer T., Gotz M. et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy. 2008; 63: 5–34.Bacharier L. B., Boner A., Carlsen K. H., Eigenmann P. A., Frischer T., Gotz M. et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy. 2008; 63: 5–34.National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda (MD): National Heart, Lung, and Blood Institute (US). 2007. URL: http://www.ncbi.nlm.nih. gov/books/NBK7232, accessed May 20, 2013.National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda (MD): National Heart, Lung, and Blood Institute (US). 2007. URL: http://www.ncbi.nlm.nih. gov/books/NBK7232, accessed May 20, 2013.British Thoracic Society and Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma: A National Clinical Guideline. British Thoracic Society and Scottish Intercollegiate Guidelines Network, 2011. Available from: http://www.sign.ac.uk/guidelines/fulltext/101/index.htmlBritish Thoracic Society and Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma: A National Clinical Guideline. British Thoracic Society and Scottish Intercollegiate Guidelines Network, 2011. Available from: http://www.sign.ac.uk/guidelines/fulltext/101/index.htmlAgache I., Akdis C., Jutel M., Virchow J. C. Untangling asthma phenotypesand endotypes. Allergy. 2012; 67: 835–846.Agache I., Akdis C., Jutel M., Virchow J. C. Untangling asthma phenotypesand endotypes. Allergy. 2012; 67: 835–846.Hamid Q., Tulic M. Immunobiology of asthma. Annu Rev Physiol. 2009; 71: 489–507.Hamid Q., Tulic M. Immunobiology of asthma. Annu Rev Physiol. 2009; 71: 489–507.Joos G. F. The role of neuroeffector mechanisms in the pathogenesis of asthma. Curr Allergy Asthma Rep. 2001; 1: 134–143.Joos G. F. The role of neuroeffector mechanisms in the pathogenesis of asthma. Curr Allergy Asthma Rep. 2001; 1: 134–143.Fixman E. D., Stewart A., Martin J. G. Basic mechanisms of development of airway structural changes in asthma. Eur Respir J. 2007; 29: 379–389.Fixman E. D., Stewart A., Martin J. G. Basic mechanisms of development of airway structural changes in asthma. Eur Respir J. 2007; 29: 379–389.Malmstrom K., Pelkonen A. S., Malmberg L. P., Sarna S., Lindahl H., Kajosaari M. et al. Lung function, airway remodeling and inflammation in symptomatic infants: outcome at 3 years. Thorax. 2011; 66: 157–162.Malmstrom K., Pelkonen A. S., Malmberg L. P., Sarna S., Lindahl H., Kajosaari M. et al. Lung function, airway remodeling and inflammation in symptomatic infants: outcome at 3 years. Thorax. 2011; 66: 157–162.Bossley C. J., Fleming L., Gupta A., Regamey N., Frith J., Oates T. et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T (H)2 cytokines. J Allergy Clin Immunol. 2012; 129: 974–982.Bossley C. J., Fleming L., Gupta A., Regamey N., Frith J., Oates T. et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T (H)2 cytokines. J Allergy Clin Immunol. 2012; 129: 974–982.Bozzetto S., Carraro S., Giordano G., Boner A., Baraldi E. Asthma, allergy and respiratory infections: the vitamin D hypothesis. Allergy. 2012; 67: 10–17.Bozzetto S., Carraro S., Giordano G., Boner A., Baraldi E. Asthma, allergy and respiratory infections: the vitamin D hypothesis. Allergy. 2012; 67: 10–17.Martinez F. D. New insights into the natural history of asthma: primary prevention on the horizon. J Allergy Clin Immunol. 2011; 128: 939–945.Martinez F. D. New insights into the natural history of asthma: primary prevention on the horizon. J Allergy Clin Immunol. 2011; 128: 939–945.Аллергия у детей: от теории — к практике. Под ред. Л. С. Намазовой-Барановой. М.: Союз педиатров России. 2010–2011. 668 с.Аллергия у детей: от теории — к практике. Под ред. Л. С. Намазовой-Барановой. М.: Союз педиатров России. 2010–2011. 668 с.Баранов А.А., Вишнева Е.А., Намазова-Баранова Л.С. Телемедицина — перспективы и трудности перед новым этапом развития. Педиатрическая фармакология. 2013; 10 (3): 6–11.Баранов А.А., Вишнева Е.А., Намазова-Баранова Л.С. Телемедицина — перспективы и трудности перед новым этапом развития. Педиатрическая фармакология. 2013; 10 (3): 6–11.Lodrup Carlsen K. C., Soderstrom L., Mowinckel P., Haland G., Pettersen M., Munthe Kaas M. C. et al. Asthma prediction in school children; the value of combined IgE-antibodies and obstructive airways disease severity score. Allergy. 2010; 65: 1134–1140.Lodrup Carlsen K. C., Soderstrom L., Mowinckel P., Haland G., Pettersen M., Munthe Kaas M. C. et al. Asthma prediction in school children; the value of combined IgE-antibodies and obstructive airways disease severity score. Allergy. 2010; 65: 1134–1140.Price D., Musgrave S. D., Shepstone L., Hillyer E. V., Sims E. J., Gilbert R. F. et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med. 2011; 364: 1695–1707.Price D., Musgrave S. D., Shepstone L., Hillyer E. V., Sims E. J., Gilbert R. F. et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med. 2011; 364: 1695–1707.Stelmach I., Grzelewski T., Majak P., Jerzynska J., Stelmach W., Kuna P. Effect of different antiasthmatic treatments on exerciseinduced bronchoconstriction in children with asthma. J Allergy Clin Immunol. 2008; 121: 383–389.Stelmach I., Grzelewski T., Majak P., Jerzynska J., Stelmach W., Kuna P. Effect of different antiasthmatic treatments on exerciseinduced bronchoconstriction in children with asthma. J Allergy Clin Immunol. 2008; 121: 383–389.Asthma Management Handbook. National Asthma Council Australia, Melbourne, 2006. Available from: http://www.nationalasthma.org.au/handbookAsthma Management Handbook. National Asthma Council Australia, Melbourne, 2006. Available from: http://www.nationalasthma.org.au/handbookPrice D., Musgrave S. D., Shepstone L., Hillyer E. V., Sims E. J., Gilbert R. F. et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med. 2011; 364: 1695–1707.Price D., Musgrave S. D., Shepstone L., Hillyer E. V., Sims E. J., Gilbert R. F. et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med. 2011; 364: 1695–1707.Garcia Garcia M. L., Wahn U., Gilles L., Swern A., Tozzi C. A., Polos P. Montelukast, compared with fluticasone, for control of asthma among 6-to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics. 2005; 116: 360–369.Garcia Garcia M. L., Wahn U., Gilles L., Swern A., Tozzi C. A., Polos P. Montelukast, compared with fluticasone, for control of asthma among 6-to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics. 2005; 116: 360–369.Stelmach I., Grzelewski T., Majak P., Jerzynska J., Stelmach W., Kuna P. Effect of different antiasthmatic treatments on exerciseinduced bronchoconstriction in children with asthma. J Allergy Clin Immunol. 2008; 121: 383–389.Stelmach I., Grzelewski T., Majak P., Jerzynska J., Stelmach W., Kuna P. Effect of different antiasthmatic treatments on exerciseinduced bronchoconstriction in children with asthma. J Allergy Clin Immunol. 2008; 121: 383–389.Pelkonen A. S., Malmstrom K., Sarna S., Kajosaari M., Klemola T., Malmberg L. P., Makela M. J. The effect of montelukast on respiratory symptoms and lung function in wheezy infants. Eur Respir J. 2013 Mar; 41 (3): 664–70. Doi: 10.1183/09031936.00173411. Epub 2012 Jul 12.Pelkonen A. S., Malmstrom K., Sarna S., Kajosaari M., Klemola T., Malmberg L. P., Makela M. J. The effect of montelukast on respiratory symptoms and lung function in wheezy infants. Eur Respir J. 2013 Mar; 41 (3): 664–70. Doi: 10.1183/09031936.00173411. Epub 2012 Jul 12.Ducharme F. M., Ni Chroinin M., Green-stone I., Lasserson T. J. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010: CD005533.Ducharme F. M., Ni Chroinin M., Green-stone I., Lasserson T. J. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010: CD005533.Ducharme F. M., Ni Chroinin M., Green-stone I., Lasserson T. J. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010: CD005535.Ducharme F. M., Ni Chroinin M., Green-stone I., Lasserson T. J. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010: CD005535.Nishimuta T., Kondo N., Hamasaki Y., Morikawa A., Nishima S. Japanese guideline for childhood asthma. Allergol Int. 2011; 60: 147–169.Nishimuta T., Kondo N., Hamasaki Y., Morikawa A., Nishima S. Japanese guideline for childhood asthma. Allergol Int. 2011; 60: 147–169.Куличенко Т.В., Намазова-Баранова Л.С., Торшхоева Р.М., Лукина О.Ф., Вишнева Е.А. Анти-IgE-терапия тяжелой бронхиальной астмы у детей: двухлетний опыт. Педиатрическая фармакология. 2010; 7(3): 57–65.Куличенко Т.В., Намазова-Баранова Л.С., Торшхоева Р.М., Лукина О.Ф., Вишнева Е.А. Анти-IgE-терапия тяжелой бронхиальной астмы у детей: двухлетний опыт. Педиатрическая фармакология. 2010; 7(3): 57–65.Куличенко Т. В., Баранов А. А., Абелевич М. М., Балашова Е. В., Вишнева Е. А. и др. Обобщенный анализ применения моноклональных антител к IgE в лечении бронхиальной астмы у детей в РФ. Педиатрическая фармакология. 2011; 8 (2): 50–56.Куличенко Т. В., Баранов А. А., Абелевич М. М., Балашова Е. В., Вишнева Е. А. и др. Обобщенный анализ применения моноклональных антител к IgE в лечении бронхиальной астмы у детей в РФ. Педиатрическая фармакология. 2011; 8 (2): 50–56.Busse W., Raphael G. D., Galant S., Kalberg C., Goode-Sellers S., Srebro S. et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol. 2001; 107: 461–468.Busse W., Raphael G. D., Galant S., Kalberg C., Goode-Sellers S., Srebro S. et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol. 2001; 107: 461–468.Szefler S. J., Phillips B. R., Martinez F. D., Chin-chilli V. M., Lemanske R. F., Strunk R. C. et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005; 115: 233–242.Szefler S. J., Phillips B. R., Martinez F. D., Chin-chilli V. M., Lemanske R. F., Strunk R. C. et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005; 115: 233–242.Laube B. L., Janssens H. M., de Jongh F. H., Devadason S. G., Dhand R., Diot P. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011; 37: 1308–1331.Laube B. L., Janssens H. M., de Jongh F. H., Devadason S. G., Dhand R., Diot P. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011; 37: 1308–1331.Burks A. W., Calderon M. A., Casale T., Cox L., Demoly P., Jutel M. et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensusreport. J Allergy Clin Immunol. 2013; 1 31: 1288–1296.Burks A. W., Calderon M. A., Casale T., Cox L., Demoly P., Jutel M. et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensusreport. J Allergy Clin Immunol. 2013; 1 31: 1288–1296.European Academy of Allergy and Clinical Immunology. European Declaration on Allergen Immunotherapy. European Academy of Allergy and Clinical Immunology, 2011. Available from: eaaci.net.European Academy of Allergy and Clinical Immunology. European Declaration on Allergen Immunotherapy. European Academy of Allergy and Clinical Immunology, 2011. Available from: eaaci.net.Minai B. A., Martin J. E., Cohn R. C. Results of a physician and respiratory therapist collaborative effort to improve long-term metered-dose inhaler technique in a pediatric asthma clinic. Respir Care. 2004; 49: 600–605.Minai B. A., Martin J. E., Cohn R. C. Results of a physician and respiratory therapist collaborative effort to improve long-term metered-dose inhaler technique in a pediatric asthma clinic. Respir Care. 2004; 49: 600–605.van der Valk R. J., Baraldi E., Stern G., Frey U., de Jongste J. C. Daily exhaled nitric oxide measurements and asthma exacerbations in children. Allergy. 2012; 67: 265–271.van der Valk R. J., Baraldi E., Stern G., Frey U., de Jongste J. C. Daily exhaled nitric oxide measurements and asthma exacerbations in children. Allergy. 2012; 67: 265–271.Jackson D. J., Sykes A., Mallia P., Johnston S. L. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol. 2011; 128: 1165–1174.Jackson D. J., Sykes A., Mallia P., Johnston S. L. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol. 2011; 128: 1165–1174.FitzGerald J. M., Shragge D., Haddon J., Jennings B., Lee J., Bai T. et al. A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation. Can Respir J. 2000; 7: 61–67.FitzGerald J. M., Shragge D., Haddon J., Jennings B., Lee J., Bai T. et al. A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation. Can Respir J. 2000; 7: 61–67.Ducharme F. M., Lemire C., Noya F. J., Davis G. M., Alos N., Leblond H. et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med. 2009; 360: 339–353.Ducharme F. M., Lemire C., Noya F. J., Davis G. M., Alos N., Leblond H. et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med. 2009; 360: 339–353.Robertson C. F., Price D., Henry R., Mellis C., Glasgow N., Fitzgerald D. et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med. 2007; 175: 323–329.Robertson C. F., Price D., Henry R., Mellis C., Glasgow N., Fitzgerald D. et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med. 2007; 175: 323–329.Szefler S. J. Advancing asthma care: the glass is only half full! J Allergy Clin Immunol. 2011; 128: 485–494.Szefler S. J. Advancing asthma care: the glass is only half full! J Allergy Clin Immunol. 2011; 128: 485–494.Намазова Л.С., Куличенко Т.В., Торшхоева Р.М. Опыт лечения омализумабом подростков с тяжелой атопической бронхиальной астмой. Педиатрическая фармакология. 2008; 5 (6): 30–34.Намазова Л.С., Куличенко Т.В., Торшхоева Р.М. Опыт лечения омализумабом подростков с тяжелой атопической бронхиальной астмой. Педиатрическая фармакология. 2008; 5 (6): 30–34.

The authors declare that there are no conflicts of interest present.